[go: up one dir, main page]

PE20030943A1 - Agonistas del receptor b3-adrenergico - Google Patents

Agonistas del receptor b3-adrenergico

Info

Publication number
PE20030943A1
PE20030943A1 PE2003000180A PE2003000180A PE20030943A1 PE 20030943 A1 PE20030943 A1 PE 20030943A1 PE 2003000180 A PE2003000180 A PE 2003000180A PE 2003000180 A PE2003000180 A PE 2003000180A PE 20030943 A1 PE20030943 A1 PE 20030943A1
Authority
PE
Peru
Prior art keywords
phenyl
oxazol
hydroxy
amino
alkyl
Prior art date
Application number
PE2003000180A
Other languages
English (en)
Inventor
Bradley Paul Morgan
Jennifer Anne Lafontaine
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20030943A1 publication Critical patent/PE20030943A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A COMPUESTOS HETEROCICLICOS AGONISTAS DEL RECEPTOR ß-ADRENERGICO DE FORMULA I DONDE Ar ES FENILO, HETEROCICLICO AROMATICO O NO CON 1 A 4 HETEROATOMOS DE O, S, N; R1 Y R2 SON H, OH, HALOGENO, ENTRE OTROS; R3 Y R4 SON H, ALQUILO C1-C6; R5 ES H, ALQUILO C1-C6; R6 Y R7 SON H, HALOGENO, ALQUILO C1-C6; R8 ES -CONR1bR2b, -SOR1b, -SO2R1b, ENTRE OTROS; X ES -O-, -NH-, CH2, ENTRE OTROS; m ES 0-1; HET ES IMIDAZOL, OXAZOL, PIRAZOL ENTRE OTROS; R1b Y R2b SON H, AMINO, AMINOARILO ENTRE OTROS. SON COMPUESTOS PREFERIDOS 2-(4-(4-(2-(2(R)-HIDROXI-2-(6-METILPIRIDIN-3-IL)ETIL-AMINO)ETOXI}FENIL)OXAZOL-2-IL)-N,N-DIMETILACETAMIDA, 2-(4-{4-(2-(2(R)-HIDROXI-2-PIRIDIN-3-ILETILAMINO)-ETOXI]FENIL}OXAZOL-2-IL)-N,N-DIMETILACETAMIDA, N,N-DIETIL-2-(4-{4-(2-(2(R)-HIDROXI-2-PIRIDIN-3-ILETIL-AMINO)ETOXI]FENIL})OXAZOL-2-IL)ACETAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA EN LA QUE EL OTRO AGENTE FARMACEUTICO SE SELECCIONA DE INHIBIDOR DE LA SECRECION DE APOLIPOPROTEINA-B/PROTEINA DE TRANSFERENCIA DE TRIGLICERIDOS, UN AGONISTA DE COLECISTOQUININA-A, UN AGONISTA DE MCR-4, UN ANTAGONISTA DEL RECEPTOR DE CANNABINOIDES ENTRE OTROS. LA COMPOSICION PRESENTA ACTIVIDAD HIPOGLICEMICA Y ES UTIL PARA EL TRATAMIENTO DE LA OBESIDAD
PE2003000180A 2002-02-27 2003-02-24 Agonistas del receptor b3-adrenergico PE20030943A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36025102P 2002-02-27 2002-02-27

Publications (1)

Publication Number Publication Date
PE20030943A1 true PE20030943A1 (es) 2003-11-08

Family

ID=27766207

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000180A PE20030943A1 (es) 2002-02-27 2003-02-24 Agonistas del receptor b3-adrenergico

Country Status (13)

Country Link
EP (1) EP1485379A1 (es)
JP (1) JP2005518448A (es)
AU (1) AU2003248356A1 (es)
BR (1) BR0308070A (es)
CA (1) CA2476316A1 (es)
DO (1) DOP2003000587A (es)
GT (1) GT200300043A (es)
MX (1) MXPA04007127A (es)
PA (1) PA8567701A1 (es)
PE (1) PE20030943A1 (es)
TW (1) TW200408637A (es)
UY (1) UY27680A1 (es)
WO (1) WO2003072572A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085297A2 (en) 2001-04-24 2002-10-31 East Carolina University Compositions & formulations with a non-glucocorticoid steroid &/or a ubiquinone & kit for treatment of respiratory & lung disease
US7405207B2 (en) 2002-06-17 2008-07-29 Epigenesis Pharmaceuticals, Inc. Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
GB0324654D0 (en) * 2003-10-22 2003-11-26 Glaxo Group Ltd Medicinal compounds
WO2005061433A2 (en) * 2003-12-23 2005-07-07 Astellas Pharma Inc. Aminoalcohol derivatives
DE102004021779A1 (de) * 2004-04-30 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
US8685924B2 (en) 2004-08-25 2014-04-01 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
US20150087832A1 (en) 2011-10-27 2015-03-26 Merck Sharp & Dohme, Corp. Process for making beta 3 agonists and intermediates
ES2584427T3 (es) 2011-10-27 2016-09-27 Merck Sharp & Dohme Corp. Proceso para la preparación de agonistas beta 3 y productos intermedios
DK2968269T3 (da) 2013-03-15 2019-10-07 Merck Sharp & Dohme Fremgangsmåde til fremstilling af beta-3-agonister og mellemprodukter
CN110869022A (zh) 2017-06-06 2020-03-06 乌洛万特科学有限公司 使用维贝隆以治疗膀胱过度活动症
AU2019393372B2 (en) 2018-12-05 2025-08-21 Sumitomo Pharma Co., Ltd Vibegron for the treatment of overactive bladder symptoms

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO179246C (no) * 1991-11-20 1996-09-04 Sankyo Co Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
AU684352B2 (en) * 1994-04-08 1997-12-11 Sumitomo Chemical Company, Limited Ether compound, use thereof, and intermediate for producing the compound
WO1996035671A1 (en) * 1995-05-10 1996-11-14 Pfizer Inc. β-ADRENERGIC AGONISTS
GB9812709D0 (en) * 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
CZ20031012A3 (en) * 2000-10-20 2004-04-14 Pfizer Products Inc. Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists

Also Published As

Publication number Publication date
MXPA04007127A (es) 2005-07-05
CA2476316A1 (en) 2003-09-04
JP2005518448A (ja) 2005-06-23
DOP2003000587A (es) 2003-08-30
EP1485379A1 (en) 2004-12-15
PA8567701A1 (es) 2003-11-12
AU2003248356A1 (en) 2003-09-09
WO2003072572A1 (en) 2003-09-04
BR0308070A (pt) 2004-12-21
TW200408637A (en) 2004-06-01
GT200300043A (es) 2003-09-22
UY27680A1 (es) 2003-10-31
WO2003072572A8 (en) 2004-01-29

Similar Documents

Publication Publication Date Title
PE20090434A1 (es) Derivados de sulfonil amida como inhibidores de quinasas
PE20030943A1 (es) Agonistas del receptor b3-adrenergico
PE20090837A1 (es) Nuevos compuestos quimicos
PE20110308A1 (es) 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa
PE20141375A1 (es) Activadores de glucoquinasa
PE20000947A1 (es) ACTIVADORES DE hPPARþ Y hPPARO
PE20110341A1 (es) COMPUESTOS HETEROCICLICOS QUE MODULAN LA ACTIVIDAD DE LA ESTEROIL-CoA-DESATURASA
PE20081199A1 (es) Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa
CO6150170A2 (es) Derivados de 1-(-d-glucopiranosil)-3-(4-ciclopropilfenilmetil)-4-halogeno indol y uso de los mismos como inhibidores de los transportadores de glucosa dependientes de sodio
PE20090641A1 (es) Amidas heterociclicas
PE20071022A1 (es) Compuestos derivados de dibencilamina como inhibidores de la proteina de transferencia del colesteril ester (cept)
PE20120136A1 (es) Compuestos derivados de n-acilsulfonamidas como inhibidores de bcl-2
PE20010406A1 (es) ACIDO 2-{2-METIL-4[({4-METIL-2[4-(TRIFLUOROMETIL)FENIL]-1,3-TIAZOL-5-IL}METIL)SULFANIL]FENOXI}ACETICO COMO AGONISTA DEL hPPARd
PE20051146A1 (es) Compuestos heterociclicos anticitocina
HRP20100326T1 (hr) 2-aminoariloksazolni spojevi kao inhibitori tirozinske kinaze
DE60204718D1 (de) 3-substituierte oxindol beta 3 agonisten
PE20090617A1 (es) Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa
PE20090606A1 (es) Nuevos inhibidores de catepsina c y uso
PE20090815A1 (es) Compuesto de amida
PE20081545A1 (es) Derivados de sulfonamida como inhibidores de acido graso sintasas
ATE390922T1 (de) 2-aminobenzothiazole als cb1 rezeptor inverse agonisten
PE20091673A1 (es) Nuevos derivados de carbazol, inhibidores de hsp90, composiciones que los contienen y utilizacion
PE20040987A1 (es) Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf)
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
TW200518750A (en) Cornea-conjunctiva disorder treating agent

Legal Events

Date Code Title Description
FA Abandonment or withdrawal